8-K: Ainos Inc. Secures Exclusive Patent License, Bolsters AI Nose Technology

Ainos Inc. has entered into a patent license agreement with Taiwan Carbon Nano Technology Corporation (TCNT), acquiring exclusive rights to gas sensor and medical device patents in exchange for 5.5 million shares of common stock.

Summary

• Ainos Inc. entered into a patent license agreement with Taiwan Carbon Nano Technology Corporation (TCNT) on August 6, 2024.
• Ainos will receive an exclusive, irrevocable, and perpetual license for certain gas sensor and medical device patents.
• In exchange, Ainos will issue 5.5 million shares of its common stock to TCNT.
• The share price will be valued at 1.05 times the highest closing price of Ainos stock during the 30 trading days prior to the agreement's effective date.
• Following the share issuance, TCNT will control approximately 63.2% of Ainos' voting power.
• TCNT plans to enter a voting agreement with Ainos KY, agreeing to vote its shares as directed by Ainos KY.
• Ainos also prepaid a $1.67 million convertible note, using $1.44 million in cash and issuing 382,384 shares valued at $0.588 per share.
• Lawrence K. Lin transitioned from his role as Executive Vice President of Operations on August 9, 2024.

Sentiment

Score: 5

Explanation: The document contains both positive and negative aspects. The acquisition of exclusive patent rights is a positive development, but the significant dilution of shares and increased control by TCNT are concerning for existing shareholders. The sentiment is therefore neutral to slightly negative.

Positives

• Ainos has gained exclusive access to valuable gas sensor and medical device patents, enhancing its AI Nose and point-of-care testing (POCT) technologies.
• The patent license agreement is structured to preserve cash, as the consideration is in the form of shares rather than cash.
• The agreement is perpetual and irrevocable, providing long-term security for Ainos' technology.

Negatives

• The issuance of 5.5 million shares to TCNT will significantly dilute existing shareholders.
• TCNT will gain a controlling stake of 63.2% in Ainos, potentially reducing the influence of other shareholders.
• The company used $1.44 million in cash to prepay the convertible note, reducing its cash reserves.

Risks

• The increased control of TCNT could lead to decisions that may not align with the interests of all shareholders.
• The dilution of shares could negatively impact the stock price.
• The company's cash reserves have been reduced by $1.44 million due to the note prepayment.

Future Outlook

The company expects to benefit from the exclusive license to the gas sensor and medical device patents, enhancing its technology offerings. TCNT's increased voting power and planned voting agreement with Ainos KY will likely influence the company's future direction.

Management Comments

• The patent license agreement is an effort to bolster the Company's AI Nose and point-of-care testing (POCT) technologies while preserving cash.

Industry Context

This agreement reflects a trend in the medical technology industry where companies seek to acquire intellectual property to enhance their product offerings and competitive advantage. The focus on AI and point-of-care testing aligns with current market demands for advanced diagnostic solutions.

Comparison to Industry Standards

• The licensing agreement is similar to other deals in the biotech and medtech sectors where companies acquire intellectual property to expand their product portfolios.
• The valuation of the shares issued for the license is based on a premium to the market price, which is a common practice in such transactions.
• The level of control gained by TCNT is significant and could be compared to other instances where a major shareholder exerts considerable influence over a company's direction.
• The prepayment of the convertible note is a common financial maneuver to reduce debt and interest expenses, but the use of cash and share issuance is a trade-off between immediate cash outflow and dilution.

Management Changes

Related Party Transactions

• The patent license agreement with TCNT is a related party transaction, as TCNT previously controlled a significant portion of Ainos' voting power.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of 5.5 million shares to TCNT.
• TCNT will gain significant control over Ainos, potentially impacting the influence of other shareholders.
• Employees may be affected by the strategic changes resulting from the new patent license and TCNT's increased control.
• Customers may benefit from the enhanced technology offerings resulting from the licensed patents.

Next Steps

• TCNT will enter into a voting agreement with Ainos KY.
• Ainos will integrate the licensed patents into its technology development.
• The company will continue to develop its AI Nose and point-of-care testing technologies.

Key Dates

Keywords

Patent License, Gas Sensors, Medical Devices, AI Nose, Point-of-Care Testing, Share Issuance, Voting Power, Convertible Note, Technology, TCNT